Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H16FN2O14P3 |
| Molecular Weight | 500.1587 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@H]2O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@H](O)[C@H]2F)C(=O)NC1=O
InChI
InChIKey=RUKRVHYQIIURNV-XQXXSGGOSA-N
InChI=1S/C10H16FN2O14P3/c1-4-2-13(10(16)12-8(4)15)9-6(11)7(14)5(25-9)3-24-29(20,21)27-30(22,23)26-28(17,18)19/h2,5-7,9,14H,3H2,1H3,(H,20,21)(H,22,23)(H,12,15,16)(H2,17,18,19)/t5-,6+,7-,9-/m0/s1
| Molecular Formula | C10H16FN2O14P3 |
| Molecular Weight | 500.1587 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Clevudine (also known as L-FMAU) is a nucleos(t)ide reverse transcriptase inhibitor, which inhibits the DNA synthesis activity of the hepatitis B virus polymerase. The drug was approved in Korea and Philippines and is being marketed under the names Levovir and Revovir. The drug is indicated in patients with chronic hepatitis B virus infection. Upon administration, clevudine is metabolized to the active metabolite, clevudine triphosphate, which is responsible for the inhibition of viral polymerase.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. | 1996 Apr 12 |
|
| Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. | 1996 Feb |
|
| Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. | 1996 Jul 5 |
|
| Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. | 1999 Jun 15 |
|
| In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. | 2001 Sep |
|
| In vitro activity of potential anti-poxvirus agents. | 2003 Jan |
|
| Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. | 2003 Jan |
|
| Current and future antiviral agents for chronic hepatitis B. | 2003 Mar |
|
| Mechanism of antiviral activities of 3'-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. | 2003 Nov |
|
| Cellular and virological mechanisms of HBV drug resistance. | 2006 Feb |
|
| Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. | 2013 Sep |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:12:04 GMT 2023
by
admin
on
Sat Dec 16 08:12:04 GMT 2023
|
| Record UNII |
GYY7PAS72J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
174625-00-4
Created by
admin on Sat Dec 16 08:12:04 GMT 2023 , Edited by admin on Sat Dec 16 08:12:04 GMT 2023
|
PRIMARY | |||
|
m3621
Created by
admin on Sat Dec 16 08:12:04 GMT 2023 , Edited by admin on Sat Dec 16 08:12:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
503024
Created by
admin on Sat Dec 16 08:12:04 GMT 2023 , Edited by admin on Sat Dec 16 08:12:04 GMT 2023
|
PRIMARY | |||
|
GYY7PAS72J
Created by
admin on Sat Dec 16 08:12:04 GMT 2023 , Edited by admin on Sat Dec 16 08:12:04 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
